CBD-rich cannabis oil did not outperform placebo for knee pain

Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis.

Frontiers in pharmacology • • Clinical Trial • Highly Relevant
🤖

AI Summary

This double-blind, randomized, placebo-controlled human trial studied patients with knee osteoarthritis over 60 days. Participants received either placebo or a full-spectrum, CBD-rich Cannabis sativa oil containing 45 mg of CBD daily. The primary outcome was pain intensity measured with the WOMAC scale. Both groups improved, but the cannabis-oil group did not show a statistically significant advantage over placebo for pain.

The study also found no significant between-group differences in measures of pain, mood, sleep, or physical and mental quality of life. The oil was well tolerated: no serious adverse events or clinically significant changes in serum biomarkers were reported. However, this abstract does not provide the sample size or detailed numerical results, and it cannot establish whether other doses or formulations containing CBD, THC, or additional cannabinoids might be effective. This is an abstract-based summary, not a full-text review.

💡 Key Findings

1
In patients with knee osteoarthritis, CBD-rich cannabis oil did not significantly outperform placebo for pain intensity after 60 days.
High
95%
2
Both the placebo and cannabis groups showed comparable improvements in pain scores, with no statistically significant difference between groups.
High
95%
3
The oil was well tolerated, with no serious adverse events or clinically significant serum-biomarker changes reported.
High
90%
4
There were no significant between-group differences in mood, sleep, or physical and mental quality-of-life measures.
High
90%

📄 Original Abstract

UNLABELLED: Osteoarthritis is a common inflammatory and degenerative joint disease characterized by associated chronic pain, often ensuing to diminished quality of life. Current pain management options present small benefits and great side effects, driving interest in potential treatments such as cannabis, for its anti-inflammatory and analgesic effects. This trial aimed to assess the efficacy and safety of cannabidiol (CBD) in a full-spectrum cannabis oil in managing osteoarthritis-related pain. METHODS: Osteoarthritis patients were randomized into either placebo or cannabis groups and monitored for 60 days. The cannabis group received a CBD daily oral dose of 45 mg. Primary outcome was determined by pain intensity measured utilizing the WOMAC, while secondary outcomes included the Visual Analogue Scale (VAS) Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI) and the MC S12/PC S12 scores (mental and physical components of the quality of life SF-12 scale). RESULTS: At the end of intervention (i.e. 60 days or trial end-point), both the placebo and cannabis groups exhibited comparable improvements in pain scores, with no statistically significant differences in pain intensity observed between groups. Likewise, secondary outcomes showed no significant differences between groups. Furthermore, the CBD-rich cannabis oil was well-tolerated, as no patients experienced any serious adverse events or clinically significant changes in serum biomarkers. CONCLUSION: CBD-rich cannabis oil treatment was well tolerated, with no serious adverse effects observed. However, this treatment did not demonstrate superiority over placebo in alleviating pain or improving secondary outcomes in osteoarthritis patients. Further multicentrical and larger trials are warranted to explore the efficacy of alternative dosages and/or formulations containing CBD, THC and other cannabinoids. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT06588972 Identifier: [NCT06588972].

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.